Literature DB >> 17611657

Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis.

Miho Tsukioka1, Yoshinari Matsumoto, Maiko Noriyuki, Chika Yoshida, Hiroyuki Nobeyama, Hiroyuki Yoshida, Tomoyo Yasui, Toshiyuki Sumi, Ken-Ichi Honda, Osamu Ishiko.   

Abstract

We immunohistochemically examined the expression of the glucose transporters (GLUT)1, GLUT3 and GLUT4, in 154 tumor samples of epithelial ovarian carcinoma. In addition, we investigated the correlations between the expression of GLUTs and the vascular endothelial growth factor (VEGF), and microvessel count and clinical parameters. The rates of expression of GLUT1, GLUT3 and GLUT4 were 98.7%, 92.8% and 84.4%, respectively. GLUT1 and GLUT4 were both strongly expressed in serous adenocarcinoma, but weakly expressed in clear cell adenocarcinoma. The expressions of GLUT1 and GLUT4 correlated with the clinical disease stage. The expressions of GLUT1, GLUT3 and GLUT4 correlated positively with VEGF expression. The expression status for GLUT1, GLUT3, GLUT4 and VEGF did not represent a prognostic factor. These findings suggest that characteristic differences in the patterns of glucose uptake can exist according to the histological type and that GLUT1, GLUT3 and GLUT4 could be related to tumor angiogenesis in epithelial ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611657

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

1.  Expression of metabolically targeted biomarkers in endometrial carcinoma.

Authors:  Heather Wahl; Sayeema Daudi; Malti Kshirsagar; Kent Griffith; Lijun Tan; Jennifer Rhode; J Rebecca Liu
Journal:  Gynecol Oncol       Date:  2009-10-29       Impact factor: 5.482

2.  Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells.

Authors:  Hans-Richard Demel; Benedikt Feuerecker; Guido Piontek; Christof Seidl; Birgit Blechert; Anja Pickhard; Markus Essler
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

3.  The role of dysregulated glucose metabolism in epithelial ovarian cancer.

Authors:  L D Kellenberger; J E Bruin; J Greenaway; N E Campbell; R A Moorehead; A C Holloway; J Petrik
Journal:  J Oncol       Date:  2010-02-17       Impact factor: 4.375

4.  Effects of delayed motherhood on hippocampal gene expression in offspring rats.

Authors:  Ping Duan; Bo Li; Caifang Li; Xuefei Han; Yan Xu; Ying Xing; Wenhai Yan
Journal:  Mol Cell Biochem       Date:  2015-05-15       Impact factor: 3.396

5.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

6.  Evaluation of Hypoxia Inducible Factor-1α and Glucose Transporter-1 Expression in Non Melanoma Skin Cancer: An Immunohistochemical Study.

Authors:  Iman Seleit; Ola Ahmed Bakry; Dalia Rifaat Al-Sharaky; Rania Abdel Aziz Ragab; Shimaa Ahmed Al-Shiemy
Journal:  J Clin Diagn Res       Date:  2017-06-01

7.  Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers.

Authors:  Anna Krzeslak; Katarzyna Wojcik-Krowiranda; Ewa Forma; Paweł Jozwiak; Hanna Romanowicz; Andrzej Bienkiewicz; Magdalena Brys
Journal:  Pathol Oncol Res       Date:  2012-01-21       Impact factor: 3.201

8.  Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review.

Authors:  Holly Butler; Omar Saulat; Barbara-Ann Guinn
Journal:  Carcinogenesis       Date:  2022-04-25       Impact factor: 4.741

9.  PGK1 Is a Key Target for Anti-Glycolytic Therapy of Ovarian Cancer: Based on the Comprehensive Analysis of Glycolysis-Related Genes.

Authors:  Rui Gou; Yuexin Hu; Ouxuan Liu; Hui Dong; Lingling Gao; Shuang Wang; Mingjun Zheng; Xiao Li; Bei Lin
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

10.  Selective growth inhibition by glycogen synthase kinase-3 inhibitors in tumorigenic HeLa hybrid cells is mediated through NF-κB-dependent GLUT3 expression.

Authors:  M Watanabe; N Abe; Y Oshikiri; E J Stanbridge; T Kitagawa
Journal:  Oncogenesis       Date:  2012-07-09       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.